Get started
Autolus Therapeutics plcAutolus Therapeutics plcAutolus Therapeutics plc

Autolus Therapeutics plc

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Options

AUTL chart


Full chart

AUTL upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪359.26 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.87 USD
Net income (FY)
‪−220.66 M‬ USD
Revenue (FY)
‪10.12 M‬ USD
Shares float
‪240.32 M‬
Beta (1Y)
1.32

About Autolus Therapeutics plc


Sector
Health Technology
Industry
Biotechnology
CEO
Christian Martin Itin
Website
autolus.com
Headquarters
London
Founded
2018
FIGI
BBG00KVT05R6
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

AUTL news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as AUTL.